Key Highlights

  • Croda International Plc (LSE:CRDA) is in focus as Brent crude near $116 a barrel raises energy and raw material cost concerns.
  • Croda has raised prices to offset higher costs while its Consumer Care division has driven growth.
  • Shares traded around 3,271 pence after half-year results in July, as investors weighed recovery in beauty and fragrances.
  • Investors are watching order visibility, pricing, Life Sciences demand and full-year results in early 2027.

Why Croda Is in Focus Today

Croda International Plc (LSE:CRDA), the Yorkshire-based specialty chemicals group, is in focus on 28 October 2026 as rising oil prices put the spotlight on chemical companies' input costs. Brent crude climbed to about $116.37 a barrel on Budget day amid the ongoing Middle East conflict, adding to pressure on energy-intensive manufacturers.

Croda makes high-value ingredients used in beauty products, pharmaceuticals, crop protection and industrial applications. While its specialty focus gives it more pricing power than commodity chemical producers, higher energy and raw material costs can still squeeze margins if they cannot be passed on quickly.

Recent Performance

Croda (LSE:CRDA) has seen improving momentum after a difficult period in 2023 and 2024, when customer destocking hit demand. Earlier in 2026, the company said it was raising prices as costs rose and reaffirmed its outlook, with first-quarter sales edging up on a constant currency basis, led by Consumer Care.

Half-year results in July were received positively, with the shares trading around 3,271 pence after the update. A major US bank had earlier raised its price target to 4,000 pence, citing beauty-led momentum, which lifted the shares to the top of the FTSE 100 in February.

Consumer Care Leads Growth

Consumer Care, Croda's largest division, includes Beauty Actives, Beauty Care, Fragrances and Flavours, and Home Care. Beauty Actives have rebounded as customers restocked and launched new products, while Fragrances and Flavours has delivered double-digit growth in recent periods.

Demand for premium skincare and fragrance ingredients has been supported by consumers trading up and by innovation in sustainable and biotech-derived ingredients, an area where Croda has invested heavily.

Life Sciences and Industrial Specialties

The Life Sciences division supplies ingredients for pharmaceuticals, including lipid systems used in drug delivery, as well as crop protection and seed enhancement. Pharma demand can be lumpy, depending on customer programmes and vaccine-related orders, while crop care is tied to agricultural cycles.

Industrial Specialties serves markets such as lubricants and polymers and is more exposed to economic cycles. Croda has said low order book visibility and volatility, including from US tariffs, have made forecasting harder.

Market Backdrop

The FTSE 100 ended Budget day slightly higher at 10,694.50. For Croda, which earns most of its revenue overseas, the UK Budget has limited direct impact, though energy policy and business costs in the UK matter for its domestic manufacturing sites.

Currency moves remain important, as a firmer pound reduces the sterling value of overseas profits. Sterling was steady at about $1.33. Interest rate decisions by the US Federal Reserve and European Central Bank could influence currency and demand trends.

What Investors Are Watching Next

Investors will monitor pricing actions to offset higher energy and raw material costs, order patterns in Consumer Care and Life Sciences, and any comment on demand visibility into 2027. Croda's full-year results, typically published in February, will provide guidance and dividend decisions.

Cost-saving programmes, capital spending discipline and progress in biotech ingredients will also be watched. Any changes in leadership or strategic direction would be significant for the shares.

Energy Costs and Pricing Power

For chemical manufacturers, energy is a major input cost. Croda operates production sites in the UK, Europe, North America and Asia, and higher oil and gas prices can lift both energy bills and the cost of raw materials derived from petrochemicals. However, Croda also uses a large share of bio-based raw materials, such as plant oils, which can behave differently from oil-based inputs.

Croda's specialty ingredients often make up a small share of a customer's final product cost but play an important role in performance, which gives the company scope to raise prices. Earlier in 2026, it said it was increasing prices to offset rising costs. Whether those increases stick without hurting volumes will be a key question for Croda International (LSE:CRDA) in the coming months.

Investors will also look for progress on cost reduction, as management has worked to streamline operations after the downturn in demand earlier in the decade.

Outlook

Croda International (LSE:CRDA) has regained momentum through beauty and fragrance demand, but rising energy costs and uncertain visibility remain challenges. Its specialty positioning and pricing power should help, although the pace of recovery in Life Sciences and industrial markets will shape earnings in 2027.